Compare Omnicom Group Inc. (OMC) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Omnicom Group Inc. vs Sanofi SA — how do they compare? Omnicom Group Inc. trades at $76.35 (market cap $20.97B), while Sanofi SA trades at $40.1 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 4.5× Omnicom Group Inc.'s market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold Omnicom Group Inc. for 63 Days and Sanofi SA for 94 Days on average.
| OMC | SNY | |
|---|---|---|
Market Cap | $20.97B | $95.18B |
Volume | 2,092,899 | 2,995,646 |
Sector | Media | Health |
52-Week High | $88.94 | $52.34 |
52-Week Low | $67.27 | $39.51 |
Typical Hold Time | 63 Days | 94 Days |
Enterprise Value | $29.05B | $114.48B |
Dividend Yield | 4.19% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Omnicom Group (OMC) trades at $74.87, down 0.31% on the day, with a bearish technical signal and mixed earnings performance. The company reported strong revenue growth to $17.27B in 2025 but posted a net loss of -$54.50M due to elevated expenses. Recent news highlights leadership in digital marketing and $3.3B in new H1 2026 billings. Valuation metrics show a high P/E of 202.35 but attractive P/S of 0.84, while analyst consensus is mixed with a $104.67 price target.
OMC presents a value opportunity with its low P/S ratio and 4.2% dividend yield, offset by profitability concerns and high debt. The stock's 39% discount to consensus target suggests upside if margin improvements materialize from recent acquisitions. Key risks include advertising market volatility and integration challenges from the Interpublic deal. Institutional activity shows mixed positioning with recent trimming by major banks.
SNY trades at $40.2, up 1.62% on the day, with a bearish technical signal from moving averages but a neutral oscillator stance. The company reported revenue of $46.72B in 2025 with a net income margin of 16.72%, and it has beaten EPS estimates for the last three quarters. Recent news highlights a significant $8B immunology alliance expansion with Regeneron, signaling strong pipeline development.
The outlook is mixed; analyst consensus leans hold (51.86%) with a buy rating at 44.44%, reflecting optimism on new drug launches but caution over future profit margin compression projected for 2026. Key risks include execution of the expanded Regeneron partnership and managing debt levels amid investing cash flow volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Omnicom Group Inc.
Omnicom is the world's second- largest ad holding company, based on annual revenue. The firm's services, which include traditional and digital advertising and public relations, are provided worldwide, with over 85% of its revenue coming from more developed regions such as North America and Europe.
Read more on OMC →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
